



SEBASTIEN PELTIER, CEO OF VALBIOTIS, TO PRESENT HIS VISION OF A DIABETES-FREE WORLD AT L'ÉCHAPPÉE VOLÉE FROM 12 TO 14 MAY IN CHANTILLY, FRANCE

Sébastien Peltier, CEO of VALBIOTIS, a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, has been selected to share his vision of a diabetes-free world at L'Echappée Volée. This is a major event that fosters useful, breakthrough innovation for the common good, in preparation for the next 15 to 20 years.

"I'm proud to be taking part in the 2017 edition of L'Echappée Volée, alongside many other industry stakeholders, all committed to using their expertise in their specific fields to create a better world. At VALBIOTIS, we fully share the humanist values promoted by this unique event, and we are thrilled to present our vision of a future diabetes-free world", comments Sébastien Peltier, CEO of VALBIOTIS

"In 2015, there were 415 million individuals worldwide with diabetes—an irreversible disease in the majority of cases—which represented \$673 billion in health expenditure in the same year. 90% have type 2 diabetes (DT2), a condition brought about by lifestyle. Before DT2 develops, there is prediabetes, a condition that is easy to identify and also reversible! Tackling prediabetes means delaying or even preventing DT2. VALBIOTIS is dedicated to developing preventive solutions for diabetes, particularly Valedia[®], a new class of preventive products which, in the future, will help millions of people all over the world with diabetes to live longer, healthier lives while limiting health expenses," adds Sébastien Peltier, CEO of VALBIOTIS

A DIABETES-FREE WORLD

Diabetes is a pressing global problem: every 6 seconds, someone dies from this disease. 415 million people currently have diabetes worldwide and this figure will have exceeded 640 million by 2040¹. A human but also economic challenge: in 2015, 12% of the world's health expenses were used to fight against this disease² which, once diagnosed, is irreversible in the majority of cases. The disease is essentially caused by our modern lifestyle.

VALBIOTIS offers an innovative solution to this worldwide challenge, offering, for the first time, nutritional solutions especially dedicated to the 527 million prediabetics around the world. Prediabetes is defined as a reversible risk condition which develops into diabetes. VALBIOTIS is thus developing the first solution in the world for preventing type 2 diabetes (90% of diabetes cases).

¹ IDF Diabetes Atlas, 2015 <http://www.idf.org/about-diabetes/facts-figures>

² <http://www.federationdesdiabetiques.org/information/definition-diabete/chiffres-monde>

WHAT IS L'ECHAPPEE VOLEE?

More than just an event, l'Echappée Volée is a do tank which fosters innovation for the common good. This 2017 edition of l'Echappée Volée will bear the theme "Exponential Happiness", or how to believe in everyone's happiness. Invited speakers from a variety of fields including health and life sciences, energy and the environment as well as arts and culture, will provide answers by sharing their vision of a new world during presentations done in Ted-Talk style.

L'Echappée Volée 2017 will bring together more than 1,000 participants, 50 startups and 40 speakers for 3 days and 2 nights from 12 to 14 May 2017 at the Capgemini Campus, Les Fontaines, Chantilly.

All information about l'Echappée Volée: <http://2017.lechappeevolee.com/fr/>

ABOUT VALBIOTIS

VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agro-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

Valbiotis was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. Valbiotis is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

All information about VALBIOTIS:

<http://valbiotis.com/>



CONTACTS

FINANCIAL COMMUNICATION

ACTIFIN

Stéphane Ruiz / Edouard de Maissin

+33 1 56 88 11 14

sruiz@actifin.fr / edemaissin@actifin.fr

PRESS RELATIONS

ALIZE RP

Caroline Carmagnol / Wendy Rigal / Laetitia Abbar

+ 33 1 54 44 36 66 / +33 1 44 54 36 66

valbiotis@alizerp.com